GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » ROC (Joel Greenblatt) %

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) ROC (Joel Greenblatt) % : -3.45% (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Hunan Er-Kang Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -3.45%.

The historical rank and industry rank for Hunan Er-Kang Pharmaceutical Co's ROC (Joel Greenblatt) % or its related term are showing as below:

SZSE:300267' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -20.88   Med: 6.26   Max: 37.7
Current: -6.99

During the past 13 years, Hunan Er-Kang Pharmaceutical Co's highest ROC (Joel Greenblatt) % was 37.70%. The lowest was -20.88%. And the median was 6.26%.

SZSE:300267's ROC (Joel Greenblatt) % is ranked worse than
71.17% of 1013 companies
in the Drug Manufacturers industry
Industry Median: 9.47 vs SZSE:300267: -6.99

Hunan Er-Kang Pharmaceutical Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Hunan Er-Kang Pharmaceutical Co ROC (Joel Greenblatt) % Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co ROC (Joel Greenblatt) % Chart

Hunan Er-Kang Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.61 5.08 -20.88 0.65 -5.34

Hunan Er-Kang Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.19 -25.77 0.49 1.14 -3.45

Competitive Comparison of Hunan Er-Kang Pharmaceutical Co's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Er-Kang Pharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Er-Kang Pharmaceutical Co's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Er-Kang Pharmaceutical Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Hunan Er-Kang Pharmaceutical Co's ROC (Joel Greenblatt) % falls into.


;
;

Hunan Er-Kang Pharmaceutical Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(107.436 + 691.486 + 78.454) - (190.897 + 0 + 52.853)
=633.626

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(91.012 + 648.345 + 78.463) - (165.704 + 0 + 60.925)
=591.191

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Hunan Er-Kang Pharmaceutical Co for the quarter that ended in Sep. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-121.344/( ( (2915.063 + max(633.626, 0)) + (2892.03 + max(591.191, 0)) )/ 2 )
=-121.344/( ( 3548.689 + 3483.221 )/ 2 )
=-121.344/3515.955
=-3.45 %

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hunan Er-Kang Pharmaceutical Co  (SZSE:300267) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Hunan Er-Kang Pharmaceutical Co ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Er-Kang Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.
Executives
Shuai Fang Wen Director
Wang Jun Wen Independent director
Zuo Tian Fang Independent director
Qi Yang Supervisors
Li Yi Guo Supervisors
Chen Wen Xian Supervisors
Wang Xiang Feng Directors, executives
Liu Ai Jun Directors, executives
Luo Lang Directors, executives
Fan Yi Securities Affairs Representative
Yang Hai Ming Directors, executives
Shuai You Wen Director
Shuai Rui Wen Director
Gao Zhen Ya Executives
Cao Zai Yun Director

Hunan Er-Kang Pharmaceutical Co Headlines

No Headlines